Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment

Enrico Bellato, Eleonora Marini, Filippo Castoldi, Nicola Barbasetti, Lorenzo Mattei, Davide Edoardo Bonasia, Davide Blonna, Enrico Bellato, Eleonora Marini, Filippo Castoldi, Nicola Barbasetti, Lorenzo Mattei, Davide Edoardo Bonasia, Davide Blonna

Abstract

Fibromyalgia syndrome is mainly characterized by pain, fatigue, and sleep disruption. The etiology of fibromyalgia is still unclear: if central sensitization is considered to be the main mechanism involved, then many other factors, genetic, immunological, and hormonal, may play an important role. The diagnosis is typically clinical (there are no laboratory abnormalities) and the physician must concentrate on pain and on its features. Additional symptoms (e.g., Raynaud's phenomenon, irritable bowel disease, and heat and cold intolerance) can be associated with this condition. A careful differential diagnosis is mandatory: fibromyalgia is not a diagnosis of exclusion. Since 1990, diagnosis has been principally based on the two major diagnostic criteria defined by the ACR. Recently, new criteria have been proposed. The main goals of the treatment are to alleviate pain, increase restorative sleep, and improve physical function. A multidisciplinary approach is optimal. While most nonsteroidal anti-inflammatory drugs and opioids have limited benefit, an important role is played by antidepressants and neuromodulating antiepileptics: currently duloxetine (NNT for a 30% pain reduction 7.2), milnacipran (NNT 19), and pregabalin (NNT 8.6) are the only drugs approved by the US Food and Drug Administration for the treatment of fibromyalgia. In addition, nonpharmacological treatments should be associated with drug therapy.

Figures

Figure 1
Figure 1
The black dots indicate the 18 tenderness points.

References

    1. Bigatti SM, Hernandez AM, Cronan TA, Rand KL. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Care and Research. 2008;59(7):961–967.
    1. Clauw DJ. Fibromyalgia: an overview. American Journal of Medicine. 2009;122(12, supplement):S3–S13.
    1. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis and Rheumatism. 2003;48(10):2916–2922.
    1. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. Journal of Rheumatology. 2005;75(6):p. 21.
    1. Gowers WR. A lecture on lumbago: its lessons and analogues: delivered at the national hospital for the paralysed and epileptic. British Medical Journal. 1904;1:117–121.
    1. Graham W. The fibrosits syndrome. Bulletin on the Rheumatic Diseases. 1953;3(8):33–34.
    1. Smythe HA, Moldofsky H. Two contributions to understanding of the “fibrositis” syndrome. Bulletin on the Rheumatic Diseases. 1977;28(1):928–931.
    1. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990. Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism. 1990;33(2):160–172.
    1. Wolfe F. New American College of Rheumatology criteria for fibromyalgia: a twenty-year journey. Arthritis Care and Research. 2010;62(5):583–584.
    1. Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research. 2010;62(5):600–610.
    1. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis and Rheumatism. 1995;38(1):19–28.
    1. Lindell L, Bergman S, Petersson IF, Jacobsson LTH, Herrstrom P. Prevalence of fibromyalgia and chronic widespread pain. Scandinavian Journal of Primary Health Care. 2000;18(3):149–153.
    1. Yunus MB. Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation. Journal of Rheumatology. 1992;19(6):846–850.
    1. Staud R, Smitherman ML. Peripheral and central sensitization in fibromyalgia: pathogenetic role. Current Pain and Headache Reports. 2002;6(4):259–266.
    1. Li J, Simone DA, Larson AA. Windup leads to characteristics of central sensitization. Pain. 1999;79(1):75–82.
    1. Mendell LM, Wall PD. Responses of single dorsal cord cells to peripheral cutaneous unmyelinated fibres. Nature. 1965;206(4979):97–99.
    1. Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain. 2001;91(1-2):165–175.
    1. Staud R, Domingo M. Evidence for abnormal pain processing in fibromyalgia syndrome. Pain Medicine. 2001;2(3):208–215.
    1. Davies SN, Lodge D. Evidence for involvement of N-methylaspartate receptors in “wind-up” of class 2 neurones in the dorsal horn of the rat. Brain Research. 1987;424(2):402–406.
    1. Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology. 1987;26(8):1235–1238.
    1. Dickenson AH. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends in Pharmacological Sciences. 1990;11(8):307–309.
    1. Staud R, Cannon RC, Mauderli AP, Robinson ME, Price DD, Vierck CJ. Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome. Pain. 2003;102(1-2):87–95.
    1. Kosek E, Hansson P. Modulatory influence on somatosensory perception from vibration and heterotopic noxious conditioning stimulation (HNCS) in fibromyalgia patients and healthy subjects. Pain. 1997;70(1):41–51.
    1. Watkins LR, Milligan ED, Maier SF. Spinal cord glia: new players in pain. Pain. 2001;93(3):201–205.
    1. Watkins LR, Milligan ED, Maier SF. Glial activation: a driving force for pathological pain. Trends in Neurosciences. 2001;24(8):450–455.
    1. Watkins LR, Maier SF. Immune regulation of central nervous system functions: from sickness responses to pathological pain. Journal of Internal Medicine. 2005;257(2):139–155.
    1. Dubner R, Hargreaves KM. The neurobiology of pain and its modulation. Clinical Journal of Pain. 1989;5(supplement 2):S1–S4.
    1. Wolfe F, Russell IJ, Vipraio G, Ross K, Anderson J. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. Journal of Rheumatology. 1997;24(3):555–559.
    1. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. Journal of Rheumatology. 1992;19(1):90–94.
    1. Hrycaj P, Stratz T, Muller W, Russell IJ, Vipraio GA, Lopez Y. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. Journal of Rheumatology. 1993;20(11):1986–1988.
    1. Houvenagel E, Forzy G, Leloire O, et al. Spinal fluid monoamines in primary fibromyalgia. Revue du Rhumatisme et des Maladies Osteo-Articulaires. 1990;57(1):21–23.
    1. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis and Rheumatism. 1992;35(5):550–556.
    1. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depression and Anxiety. 2000;121(supplement):2–19.
    1. Juhl JH. Fibromyalgia and the serotonin pathway. Alternative Medicine Review. 1998;3(5):367–375.
    1. Wood PB. Stress and dopamine: implications for the pathophysiology of chronic widespread pain. Medical Hypotheses. 2004;62(3):420–424.
    1. Malt EA, Olafsson S, Aakvaag A, Lund A, Ursin H. Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. Journal of Affective Disorders. 2003;75(1):77–82.
    1. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis and Rheumatism. 1994;37(11):1593–1601.
    1. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP. The neuroscience and endocrinology of fibromyalgia. Arthritis and Rheumatism. 1997;40(11):1928–1939.
    1. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromalgia: new features for diagnosis. Pain. 1988;32(1):21–26.
    1. Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central μ-opioid receptor availability in fibromyalgia. Journal of Neuroscience. 2007;27(37):10000–10006.
    1. Baraniuk JN, Whalen G, Cunningham J, Clauw DJ. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskeletal Disorders. 2004;5, article 48
    1. Stisi S, Cazzola M, Buskila D, et al. Etiopathogenetic mechanisms of fibromyalgia syndrome. Reumatismo. 2008;60(supplement 1):25–35.
    1. Mountz JM, Bradley LA, Modell JG, et al. Fibromyalgia in women: abnormalities of regional cerebral blood flow in the thalamus and the caudate nucleus are associated with low pain threshold levels. Arthritis and Rheumatism. 1995;38(7):926–938.
    1. Adigüzel O, Kaptanoglu E, Turgut B, Nacitarhan V. The possible effect of clinical recovery on regional cerebral blood flow deficits in fibromyalgia: a prospective study with semiquantitative SPECT. Southern Medical Journal. 2004;97(7):651–655.
    1. Kwiatek R, Barnden L, Tedman R, et al. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis & Rheumatism. 2000;43:2823–2833.
    1. Bradley LA, Sotolongo A, Alberts KR, et al. Abnormal regional cerebral blood flow in the caudate nucleus among fibromyalgia patients and non-patients is associated with insidious symptom onset. Journal of Musculoskeletal Pain. 1999;7(1-2):285–292.
    1. Wik G, Fischer H, Bragée B, Kristianson M, Fredrikson M. Retrosplenial cortical activation in the fibromyalgia syndrome. NeuroReport. 2003;14(4):619–621.
    1. Yunus MB, Young CS, Saeed SA, Mountz JM, Aldag JC. Positron emission tomography in patients with fibromyalgia syndrome and healthy controls. Arthritis Care and Research. 2004;51(4):513–518.
    1. Walitt B, Roebuck-Spencer T, Esposito G, et al. The effects of multidisciplinary therapy on positron emission tomography of the brain in fibromyalgia: a pilot study. Rheumatology International. 2007;27(11):1019–1024.
    1. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis and Rheumatism. 2002;46(5):1333–1343.
    1. Cook DB, Lange G, Ciccone DS, Liu WC, Steffener J, Natelson BH. Functional imaging of pain in patients with primary fibromyalgia. Journal of Rheumatology. 2004;31(2):364–378.
    1. Glass JM, Williams DA, Fernandez-Sanchez ML, et al. Executive function in chronic pain patients and healthy controls: different cortical activation during response inhibition in fibromyalgia. Journal of Pain. 2011;12:1219–1229.
    1. Kim SH, Chang Y, Kim JH, et al. Insular cortex is a trait marker for pain processing in fibromyalgia syndrome—blood oxygenation level-dependent functional magnetic resonance imaging study in Korea. Clinical and Experimental Rheumatology. 2011;29(6, supplement 69):S19–S27.
    1. Foerster BR, Petrou M, Harris RE, et al. Cerebral blood flow alterations in pain-processing regions of patients with fibromyalgia using perfusion MR imaging. American Journal of Neuroradiology. 2011;32:1873–1878.
    1. Skevington SM. A standardized scale to measure beliefs about controlling pain (B.P.C.Q.): a preliminary study. Psychology and Health. 1990;4:221–232.
    1. Jensen KB, Kosek E, Petzke F, et al. Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain. 2009;144(1-2):95–100.
    1. Jensen KB, Loitoile R, Kosek E, et al. Patients with fibromyalgia display less functional connectivity in the brain's pain inhibitory network. Molecular Pain. 2012;8, article 32
    1. Burgmer M, Gaubitz M, Konrad C, et al. Decreased gray matter volumes in the cingulo-frontal cortex and the amygdala in patients with fibromyalgia. Psychosomatic Medicine. 2009;71(5):566–573.
    1. Valet M, Gündel H, Sprenger T, et al. Patients with pain disorder show gray-matter loss in pain-processing structures: a voxel-based morphometric study. Psychosomatic Medicine. 2009;71(1):49–56.
    1. Lutz J, Jäger L, De Quervain D, et al. White and gray matter abnormalities in the brain of patients with fibromyalgia: a diffusion-tensor and volumetric imaging study. Arthritis and Rheumatism. 2008;58(12):3960–3969.
    1. Schmidt-Wilcke T, Luerding R, Weigand T, et al. Striatal grey matter increase in patients suffering from fibromyalgia—a voxel-based morphometry study. Pain. 2007;132(supplement 1):S109–S116.
    1. Sundgren PC, Petrou M, Harris RE, et al. Diffusion-weighted and diffusion tensor imaging in fibromyalgia patients: a prospective study of whole brain diffusivity, apparent diffusion coefficient, and fraction anisotropy in different regions of the brain and correlation with symptom severity. Academic Radiology. 2007;14(7):839–846.
    1. Harris RE, Sundgren PC, Pang Y, et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis and Rheumatism. 2008;58(3):903–907.
    1. Harris RE, Sundgren PC, Craig AD, et al. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis and Rheumatism. 2009;60(10):3146–3152.
    1. Fayed N, Garcia-Campayo J, Magallón R, et al. Localized 1H-NMR spectroscopy in patients with fibromyalgia: a controlled study of changes in cerebral glutamate/glutamine, inositol, choline, and N-acetylaspartate. Arthritis Research and Therapy. 2010;12(4, article R134)
    1. Owen DG, Bureau Y, Thomas AW, Prato FS, Lawrence KSS. Quantification of pain-induced changes in cerebral blood flow by perfusion MRI. Pain. 2008;136(1-2):85–96.
    1. Nebel MB, Gracely RH. Neuroimaging of Fibromyalgia. Rheumatic Disease Clinics of North America. 2009;35(2):313–327.
    1. Crofford LJ. The hypothalamic-pituitary-adrenal axis in the pathogenesis of rheumatic diseases. Endocrinology and Metabolism Clinics of North America. 2002;31(1):1–13.
    1. Ferraccioli G, Cavalieri F, Salaffi F, et al. Neuroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain) Journal of Rheumatology. 1990;17(7):869–873.
    1. McCain GA, Tilbe KS. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. Journal of Rheumatology. 1989;16(19):154–157.
    1. Neeck G. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scandinavian Journal of Rheumatology, Supplement. 2000;29(113):8–12.
    1. Geenen R, Jacobs JWG, Bijlsma JWJ. Evaluation and management of endocrine dysfunction in fibromyalgia. Rheumatic Disease Clinics of North America. 2002;28(2):389–404.
    1. Griep EN, Boersma JW, de Kloet ER. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. Journal of Rheumatology. 1993;20(3):469–474.
    1. Jones KD, Deodhar P, Lorentzen A, Bennett RM, Deodhar AA. Growth hormone perturbations in Fibromyalgia: a review. Seminars in Arthritis and Rheumatism. 2007;36(6):357–379.
    1. Garrison RL, Breeding PC. A metabolic basis for fibromyalgia and its related disorders: the possible role of resistance to thyroid hormone. Medical Hypotheses. 2003;61(2):182–189.
    1. Korszun A, Young EA, Engleberg NC, et al. Follicular phase hypothalamic-pituitary-gonadal axis function in women with fibromyalgia and chronic fatigue syndrome. Journal of Rheumatology. 2000;27(6):1526–1530.
    1. Samborski W, Sobieska M, Pieta P, Drews K, Brzosko M. Normal profile of sex hormones in women with primary fibromyalgia. Annales Academiae Medicae Stetinensis. 2005;51(2):23–26.
    1. El Maghraoui A, Tellal S, Achemlal L, et al. Bone turnover and hormonal perturbations in patients with fibromyalgia. Clinical and Experimental Rheumatology. 2006;24(4):428–431.
    1. Cohen H, Neumann L, Kotler M, Buskila D. Autonomic nervous system derangement in fibromyalgia syndrome and related disorders. Israel Medical Association Journal. 2001;3(10):755–760.
    1. Kooh M, Martínez-Lavín M, Meza S, et al. Simultaneous heart rate variability and polysomnographic analyses in fibromyalgia. Clinical and Experimental Rheumatology. 2003;21(4):529–530.
    1. Furlan R, Colombo S, Perego F, et al. Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. Journal of Rheumatology. 2005;32(9):1787–1793.
    1. Anderberg UM, Liu Z, Berglund L, Nyberg F. Elevated plasma levels of neuropeptide Y in female fibromyalgia patients. European Journal of Pain. 1999;3(1):19–30.
    1. Roizenblatt S, Moldofsky H, Benedito-Silva AA, Tufik S. Alpha sleep characteristics in fibromyalgia. Arthritis & Rheumatism. 2001;44:222–230.
    1. Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotropic axis. Sleep. 1998;21(6):553–566.
    1. Prinz PN, Moe KE, Dulberg EM, et al. Higher plasma IGF-1 levels are associated with increased delta sleep in healthy older men. Journals of Gerontology A. 1995;50(4):M222–M226.
    1. Bennett RM, Clark SR, Campbell SM, Burckhardt CS. Low levels of somatomedin C in patients with the fibromyalgia syndrome: a possible link between sleep and muscle pain. Arthritis and Rheumatism. 1992;35(10):1113–1116.
    1. Buskila D, Neumann L, Hazanov I, Carmi R. Familial aggregation in the fibromyalgia syndrome. Seminars in Arthritis and Rheumatism. 1996;26(3):605–611.
    1. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis and Rheumatism. 2004;50(3):944–952.
    1. Buskila D, Sarzi-Puttini P, Ablin JN. The genetics of fibromyalgia syndrome. Pharmacogenomics. 2007;8(1):67–74.
    1. Offenbaecher M, Bondy B, de Jonge S, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis & Rheumatism. 1999;42:2482–2488.
    1. Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis and Rheumatism. 2002;46(3):845–847.
    1. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158 genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science. 2003;299(5610):1240–1243.
    1. Gürsoy S, Erdal E, Herken H, Madenci E, Alaşehirli B, Erdal N. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatology International. 2003;23(3):104–107.
    1. Buskila D, Cohen H, Neuman L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Molecular Psychiatry. 2004;9(8):730–727.
    1. Yunus MB, Khan MA, Rawlings KK, Green JR, Olson JM, Shah S. Genetic linkage analysis of multicase families with fibromyalgia syndrome. Journal of Rheumatology. 1999;26(2):408–412.
    1. Middleton GD, McFarlin JE, Lipsky PE. The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis and Rheumatism. 1994;37(8):1181–1188.
    1. Tishler M, Barak Y, Paran D, Yaron M. Sleep disturbances, fibromyalgia and primary Sjogren's syndrome. Clinical and Experimental Rheumatology. 1997;15(1):71–74.
    1. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. Journal of Rheumatology. 2004;31(4):695–700.
    1. Kötter I, Neuscheler D, Günaydin I, Wernet D, Klein R. Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up. Rheumatology International. 2007;27(11):1031–1039.
    1. Ribeiro LS, Proietti FA. Interrelations between fibromyalgia, thyroid autoantibodies, and depression. Journal of Rheumatology. 2004;31(10):2036–2040.
    1. Pamuk ON, Cakir N. The frequency of thyroid antibodies in fibromyalgia patients and their relationship with symptoms. Clinical Rheumatology. 2007;26(1):55–59.
    1. Bazzichi L, Rossi A, Giuliano T, et al. Association between thyroid autoimmunity and fibromyalgic disease severity. Clinical Rheumatology. 2007;26(12):2115–2120.
    1. Wilson RB, Gluck OS, Tesser JRP, Rice JC, Meyer A, Bridges AJ. Antipolymer antibody reactivity in a subset of patients with fibromyalgia correlates with severity. Journal of Rheumatology. 1999;26(2):402–407.
    1. Jensen B, Wittrup IH, Wiik A, et al. Antipolymer antibodies in Danish fibromyalgia patients. Clinical and Experimental Rheumatology. 2004;22(2):227–229.
    1. Sarzi-Puttini P, Atzeni F, Franco MD, et al. Anti-polymer antibodies are correlated with pain and fatigue severity in patients with fibromyalgia syndrome. Autoimmunity. 2008;41(1):74–79.
    1. Katon W, Sullivan M, Walker E. Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. Annals of Internal Medicine. 2001;134(9):917–925.
    1. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. Best Practice and Research. 2003;17(4):685–701.
    1. McBeth J, Macfarlane GJ, Benjamin S, Silman AJ. Features of somatization predict the onset of chronic widespread pain: results of a large population-based study. Arthritis & Rheumatism. 2001;44:940–946.
    1. Cohen H, Neumann L, Haiman Y, Matar MA, Press J, Buskila D. Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndromes or post-traumatic fibromyalgia syndrome? Seminars in Arthritis and Rheumatism. 2002;32(1):38–50.
    1. Epstein SA, Kay G, Clauw D, et al. Psychiatric disorders in patients with fibromyalgia: a multicenter investigation. Psychosomatics. 1999;40(1):57–63.
    1. McBeth J, Silman AJ. The role of psychiatric disorders in fibromyalgia. Current Rheumatology Reports. 2001;3(2):157–164.
    1. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Archives of Internal Medicine. 2003;163(20):2433–2445.
    1. Arnold LM, Keck PE, Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics. 2000;41(2):104–113.
    1. Nørregaard J, Volkmann H, Danneskiold-Samsøe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain. 1995;61(3):445–449.
    1. Fishbain D. Evidence-based data on pain relief with antidepressants. Annals of Medicine. 2000;32(5):305–316.
    1. Katz DL, Greene L, Ali A, Faridi Z. The pain of fibromyalgia syndrome is due to muscle hypoperfusion induced by regional vasomotor dysregulation. Medical Hypotheses. 2007;69(3):517–525.
    1. Ozgocmen S, Ozyurt H, Sogut S, Akyol O, Ardicoglu O, Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. Rheumatology International. 2006;26(7):598–603.
    1. Lario BA, Alonso Valdivielso JL, López JA, Soteres CM, Viejo Bañuelos JL, Cabello AM. Fibromyalgia syndrome: overnight falls in arterial oxygen saturation. American Journal of Medicine. 1996;101(1):54–60.
    1. Staud R. Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome. Arthritis Research and Therapy. 2006;8(3, article 208)
    1. Ablin JN, Shoenfeld Y, Buskila D. Fibromyalgia, infection and vaccination: two more parts in the etiological puzzle. Journal of Autoimmunity. 2006;27(3):145–152.
    1. Rivera J, de Diego A, Trinchet M, García Monforte A. Fibromyalgia-associated hepatitis C virus infection. British Journal of Rheumatology. 1997;36(9):981–985.
    1. Nash P, Chard M, Hazleman B. Chronic Coxsackie B infection mimicking primary fibromyalgia. Journal of Rheumatology. 1989;16(11):1506–1508.
    1. Leventhal LJ, Naides SJ, Freundlich B. Fibromyalgia and parvovirus infection. Arthritis and Rheumatism. 1991;34(10):1319–1324.
    1. Buskila D, Gladman DD, Langevitz P, Urowitz S, Smythe HA. Fibromyalgia in human immunodeficiency virus infection. Journal of Rheumatology. 1990;17(9):1202–1206.
    1. Dinerman H, Steerc AC. Lyme disease associated with fibromyalgia. Annals of Internal Medicine. 1992;117(4):281–285.
    1. Hsu VM, Patella SJ, Sigal LH. ‘Chronic Lyme disease’ as the incorrect diagnosis in patients with fibromyalgia. Arthritis and Rheumatism. 1993;36(11):1493–1500.
    1. Milligan ED, O’Connor KA, Nguyen KT, et al. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. Journal of Neuroscience. 2001;21(8):2808–2819.
    1. Holguin A, O'Connor KA, Biedenkapp J, et al. HIV-1 gp120 stimulates proinflammatory cytokine-mediated pain facilitation via activation of nitric oxide synthase-I (nNOS) Pain. 2004;110(3):517–530.
    1. Thompson ME, Barkhuizen A. Fibromyalgia, hepatitis C infection, and the cytokine connection. Current Pain and Headache Reports. 2003;7(5):342–347.
    1. Gabuzda D, Wang J. Chemokine receptors and virus entry in the central nervous system. Journal of NeuroVirology. 1999;5(6):643–658.
    1. Rock RB, Gekker G, Hu S, et al. Role of microglia in central nervous system infections. Clinical Microbiology Reviews. 2004;17(4):942–964.
    1. Waylonis GW, Perkins RH. Post-traumatic fibromyalgia: a long-term follow-up. American Journal of Physical Medicine and Rehabilitation. 1994;73(6):403–412.
    1. Bell IR, Baldwin CM, Schwartz GE. Illness from low levels of environmental chemicals: relevance to chronic fatigue syndrome and fibromyalgia. American Journal of Medicine. 1998;105(3):74S–82S.
    1. Greenfield S, Fitzcharles MA, Esdaile JM. Reactive fibromyalgia syndrome. Arthritis and Rheumatism. 1992;35(6):678–681.
    1. Sim J, Madden S. Illness experience in fibromyalgia syndrome: a metasynthesis of qualitative studies. Social Science and Medicine. 2008;67(1):57–67.
    1. Schneider MJ, Brady DM, Perle SM. Commentary: differential diagnosis of fibromyalgia syndrome: proposal of a model and algorithm for patients presenting with the primary symptom of chronic widespread pain. Journal of Manipulative and Physiological Therapeutics. 2006;29(6):493–501.
    1. Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Archives of Internal Medicine. 2000;160(2):221–227.
    1. Aaron LA, Buchwald D. A review of the evidence for overlap among unexplained clinical conditions. Annals of Internal Medicine. 2001;134(9):868–881.
    1. Gilliland BC. Fibromyalgia, arthritis associated with systemic disease, and other arthritides. In: Kasper DL, Harrison TR, editors. Harrison's Principles of Internal Medicine. 16th edition. Vol. 2. New York, NY, USA: McGraw-Hill, Medical Publication Division; 2005. pp. 2055–2064.
    1. McBeth J, Mulvey MR. Fibromyalgia: mechanisms and potential impact of the ACR, 2010 classification criteria. Nature Reviews Rheumatology. 2012;8:108–116.
    1. Buskila D, Neumann L. Fibromyalgia syndrome (FM) and nonarticular tenderness in relatives of patients with FM. Journal of Rheumatology. 1997;24(5):941–944.
    1. Fitzcharles MA, Boulos P. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. Rheumatology. 2003;42(2):263–267.
    1. Choy EH, Arnold LM, Clauw DJ, et al. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. Journal of Rheumatology. 2009;36(10):2330–2334.
    1. Mease PJ, Arnold LM, Bennett R, et al. Fibromyalgia syndrome. Journal of Rheumatology. 2007;34(6):1415–1425.
    1. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. Journal of Rheumatology. 2005;32(11):2270–2277.
    1. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. Journal of Rheumatology. 2009;36(2):398–409.
    1. Wolfe F, Michaud K. Outcome and predictor relationships in fibromyalgia and rheumatoid arthritis: evidence concerning the continuum versus discrete disorder hypothesis. Journal of Rheumatology. 2009;36(4):831–836.
    1. Toda K. Preliminary diagnostic criteria for fibromyalgia should be partially revised: comment on the article by Wolfe et al. Arthritis Care and Research. 2011;63(2):308–309.
    1. Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. Journal of Rheumatology. 2011;38(6):1113–1122.
    1. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskeletal Disorders. 2007;8, article 27
    1. Arnold LM. Strategies for managing fibromyalgia. American Journal of Medicine. 2009;122(supplement 12):S31–S43.
    1. Goldenberg DL. The interface of pain and mood disturbances in the rheumatic diseases. Seminars in Arthritis and Rheumatism. 2010;40(1):15–31.
    1. Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome—a systematic review. European Journal of Pain. 2010;14(1):5–10.
    1. Mease P, Arnold LM, Choy EH, et al. Fibromyalgia syndrome module at OMERACT 9: domain construct. Journal of Rheumatology. 2009;36(10):2318–2329.
    1. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149–158.
    1. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. Journal of the American Medical Association. 2004;292(19):2388–2395.
    1. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism. 1986;29(11):1371–1377.
    1. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1, 799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis & Rheumatism. 2000;43:378–385.
    1. Goldenberg, Schaefer DL, Ryan C, Chandran K, Zlateva Gergana A. What Is the true cost of fibromyalgia to our society: results from a cross-sectional survey in the United States. Arthritis & Rheumatism. 2009;60, supplement 10:p. 104.
    1. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Annals of the Rheumatic Diseases. 2008;67(4):536–541.
    1. American Pain Society. Guideline for the Management of Pain in Fibromyalgia, American Pain Society Clinical Practice Guidelines Program. 2011,
    1. Clauw DJ. Pharmacotherapy for patients with fibromyalgia. Journal of Clinical Psychiatry. 2008;69(supplement 2):25–29.
    1. Biasi G, Manca S, Manganelli S, Marcolongo R. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. International Journal of Clinical Pharmacology Research. 1998;18(1):13–19.
    1. Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine. 2003;114(7):537–545.
    1. Llinares-Tello F, Escrivá-Moscardó S, Martínez-Pastor F, Martínez-Mascaraque P. Possible serotoninergia syndrome associated with coadministration of paroxetine tramadol. Medicina Clinica. 2007;128(11):p. 438.
    1. Littlejohn GO, Guymer EK. Fibromyalgia syndrome: which antidepressant drug should we choose. Current Pharmaceutical Design. 2006;12(1):3–9.
    1. Arnold LM. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Medicine. 2007;8(supplement 2):S63–S74.
    1. Holman AJ. Pragmatic consideration of recent randomized, placebo-controlled clinical trials for treatment of fibromyalgia. Current Pain and Headache Reports. 2008;12(6):393–398.
    1. Perahia DGS, Pritchett YL, Desaiah D, Raskin J. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? International Clinical Psychopharmacology. 2006;21(6):311–317.
    1. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care. 1992;30(6):473–483.
    1. Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain. 2008;136(3):419–431.
    1. Häuser W, Petzke F, Sommer C. Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. Journal of Pain. 2010;11(6):505–521.
    1. Katz RS, Wolfe F, Michaud K. Fibromyalgia diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis and Rheumatism. 2006;54(1):169–176.
    1. O’Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. Journal of General Internal Medicine. 2000;15(9):659–666.
    1. Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Care and Research. 2004;51(1):9–13.
    1. Häuser W, Bernardy K, Üçeyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. Journal of the American Medical Association. 2009;301(2):198–209.
    1. Staud R. Treatment of fibromyalgia and its symptoms. Expert Opinion on Pharmacotherapy. 2007;8(11):1629–1642.
    1. Beliles K, Stoudemire A. Psychopharmacologic treatment of depression in the medically III. Psychosomatics. 1998;39(3):S2–S19.
    1. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Practice and Research. 2007;21(3):499–511.
    1. Hayden JA, Van Tulder MW, Tomlinson G. Systematic review: strategies for using exercise therapy to improve outcomes in chronic low back pain. Annals of Internal Medicine. 2005;142(9):776–785.
    1. Häkkinen A, Kautiainen H, Hannonen P, Ylinen J. Strength training and stretching versus stretching only in the treatment of patients with chronic neck pain: a randomized one-year follow-up study. Clinical Rehabilitation. 2008;22(7):592–600.
    1. Jones KD, Sherman CA, Mist SD, Carson JW, Bennett RM, Li F. A randomized controlled trial of 8-form Tai chi improves symptoms and functional mobility in fibromyalgia patients. Clinical Rheumatology. 2012;31(8):1205–1214.
    1. Wang C, Schmid CH, Rones R, et al. A randomized trial of tai chi for fibromyalgia. The New England Journal of Medicine. 2010;363(8):743–754.
    1. Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. The New England Journal of Medicine. 2012;366:511–519.
    1. Hydrotherapy Association of Chartered Physiotherapists, Guidance on good practice in hydrotherapy, Chartered Society of Physiotherapy, September 2006.
    1. Verhagen AP, Cardoso JR, Bierma-Zeinstra SM. Aquatic exercise & balneotherapy in musculoskeletal conditions. Best Practice & Research Clinical Rheumatology. 2012;26:335–343.
    1. Sukenik S, Flusser D, Abu-Shakra M. The role of Spa therapy in various rheumatic diseases. Rheumatic Disease Clinics of North America. 1999;25(4):883–897.
    1. Bender T, Karagülle Z, Bálint GP, Gutenbrunner C, Bálint PV, Sukenik S. Hydrotherapy, balneotherapy, and spa treatment in pain management. Rheumatology International. 2005;25(3):220–224.
    1. Fioravanti A, Cantarini L, Guidelli GM, Galeazzi M. Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there? Rheumatology International. 2011;31(1):1–8.
    1. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150(3699):971–979.
    1. McVeigh JG, McGaughey H, Hall M, Kane P. The effectiveness of hydrotherapy in the management of fibromyalgia syndrome: a systematic review. Rheumatology International. 2008;29(2):119–130.
    1. Vlaeyen JWS, Teeken-Gruben NJG, Goossens MEJB, et al. Cognitive-educational treatment of fibromyalgia: a randomized clinical trial. I Clinical effects. Journal of Rheumatology. 1996;23(7):1237–1245.
    1. Turk DC. Cognitive-behavioral approach to the Treatment of chronic pain patients. Regional Anesthesia and Pain Medicine. 2003;28(6):573–579.
    1. Thieme K, Gracely RH. Are psychological treatments effective for fibromyalgia pain? Current Rheumatology Reports. 2009;11(6):443–450.
    1. Munguía-Izquierdo D, Legaz-Arrese A. Exercise in warm water decreases pain and improves cognitive function in middle-aged women with fibromyalgia. Clinical and Experimental Rheumatology. 2007;25(6):823–830.
    1. Tomas-Carus P, Gusi N, Häkkinen A, Häkkinen K, Leal A, Ortega-Alonso A. Eight months of physical training in warm water improves physical and mental health in women with fibromyalgia: a randomized controlled trial. Journal of Rehabilitation Medicine. 2008;40(4):248–252.
    1. Gusi N, Tomas-Carus P. Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial. Arthritis Research and Therapy. 2008;10(1, article R24)
    1. André-Obadia N, Peyron R, Mertens P, Mauguière F, Laurent B, Garcia-Larrea L. Transcranial magnetic stimulation for pain control. Double-blind study of different frequencies against placebo, and correlation with motor cortex stimulation efficacy. Clinical Neurophysiology. 2006;117(7):1536–1544.
    1. Graff-Guerrero A, González-Olvera J, Fresán A, Gómez-Martín D, Méndez-Núñez JC, Pellicer F. Repetitive transcranial magnetic stimulation of dorsolateral prefrontal cortex increases tolerance to human experimental pain. Cognitive Brain Research. 2005;25(1):153–160.
    1. Nahmias F, Debes C, de Andrade DC, Mhalla A, Bouhassira D. Diffuse analgesic effects of unilateral repetitive transcranial magnetic stimulation (rTMS) in healthy volunteers. Pain. 2009;147(1–3):224–232.
    1. Summers J, Johnson S, Pridmore S, Oberoi G. Changes to cold detection and pain thresholds following low and high frequency transcranial magnetic stimulation of the motor cortex. Neuroscience Letters. 2004;368(2):197–200.
    1. Valmunen T, Pertovaara A, Taiminen T, Virtanen A, Parkkola R, Jääskeläinen SK. Modulation of facial sensitivity by navigated rTMS in healthy subjects. Pain. 2009;142(1-2):149–158.
    1. Fregni F, Freedman S, Pascual-Leone A. Recent advances in the treatment of chronic pain with non-invasive brain stimulation techniques. Lancet Neurology. 2007;6(2):188–191.
    1. Lefaucheur JP. The use ofrepetitive transcranial magnetic stimulation (rTMS) inchronic neuropathic pain. Neurophysiologie Clinique. 2006;36(3):117–124.
    1. Khedr EM, Kotb H, Kamel NF, Ahmed MA, Sadek R, Rothwell JC. Longlasting antalgic effects of daily sessions of repetitive transcranial magnetic stimulation in central and peripheral neuropathic pain. Journal of Neurology, Neurosurgery and Psychiatry. 2005;76(6):833–838.
    1. Defrin R, Grunhaus L, Zamir D, Zeilig G. The effect of a series of repetitive transcranial magnetic stimulations of the motor cortex on central pain after spinal cord injury. Archives of Physical Medicine and Rehabilitation. 2007;88(12):1574–1580.
    1. Katayama Y, Yaniamoto T, Kobayashi K, Oshima H, Fukaya C. Deep brain and motor cortex stimulation for post-stroke movement disorders and post-stroke pain. Acta Neurochirurgica, Supplementum. 2003;(87):121–123.
    1. Nuti C, Peyron R, Garcia-Larrea L, et al. Motor cortex stimulation for refractory neuropathic pain: four year outcome and predictors of efficacy. Pain. 2005;118(1-2):43–52.
    1. Tsubokawa T, Katayama Y, Yamamoto T, Hirayama T, Koyama S. Chronic motor cortex stimulation for the treatment of central pain. Acta Neurochirurgica, Supplement. 1991;52:137–139.
    1. Mhalla A, Baudic S, De Andrade DC, et al. Long-term maintenance of the analgesic effects of transcranial magnetic stimulation in fibromyalgia. Pain. 2011;152(7):1478–1485.
    1. Park DC, Glass JM, Minear M, Crofford LJ. Cognitive function in fibromyalgia patients. Arthritis & Rheumatism. 2001;44:2125–2133.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera